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Background: Recent developments related to a safe and effective nonabsorbable antibiotic, rifaximin, and
identification of postinfectious irritable bowel syndrome as a frequent sequela call for a need to reconsider the
value of primary prevention of traveler’s diarrhea (TD) with antibiotics.
Methods: Randomized, placebo-controlled, double-blind studies evaluating the effectiveness and safety of rifaximin
or a fluoroquinolone chemoprophylaxis against TD were pooled using a random effects model and assessed for
heterogeneity.
Results: The nine studies (four rifaximin and five fluoroquinolone) included resulted in pooled relative risk estimates
of 0.33 (95% CI = 0.24–0.45, I2 = 3.1%) and 0.12 (95% CI = 0.07–0.20, I2 =0.0%), respectively. Similar rates of
treatment emergent adverse events were found between antibiotic and placebo groups.
Conclusions: This meta-analysis supports the effectiveness of antibiotics in preventing TD. However, further studies
that include prevention of secondary chronic health outcomes among travelers to different geographic regions, and
a formal risk-benefit analysis for antibiotic chemoprophylaxis, are needed.
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Travelers’ diarrhea (TD) is one of the most frequent health
problems encountered by individuals traveling from devel-
oped to less-developed countries [1]. Although the illness
rarely results in a serious health outcome, these infections of
predominantly bacterial origin can cause significant morbid-
ity and costs resulting from incapacitation while traveling
and can disrupt valuable business and leisure excursions.
Furthermore, evidence is accumulating that these infections
can lead to long-term health consequences, including func-
tional bowel disorders such as irritable bowel syndrome [2].
Such recognition of the acute and chronic impacts of these
infections has raised the importance of primary disease
prevention.
Prevention of TD is challenging because of the ubiqui-
tous exposure to individuals through contaminated food,
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distribution, and reproduction in any mediumdeveloping world. Travelers are frequently counseled on
preventive risk behaviors, but, despite a traveler’s best at-
tention to such recommendations, evidence is lacking that
such precautions have any protective effect [3]. Although
vaccines for many of the agents commonly associated with
TD are under development, this is considered a long-term
solution and might likely suffer from lack of utilization as
has been seen with most travel-associated vaccines [4-8].
Antimicrobial prophylaxis has been considered an option
to prevent infection. In 1985, issues surrounding prophy-
laxis were debated during a National Institutes of Health
(NIH)-sponsored consensus meeting, which concluded that
routine antibiotic chemoprophylaxis should not be used be-
cause of concerns about the development of antibiotic re-
sistance, the demonstrated efficacy of empiric therapy after
the development of symptoms, and the potential for un-
necessary side effects [9]. Since that meeting, studies that
have examined the costs versus benefits of chemoprophy-
laxis for the prevention of TD have recommended against
prophylaxis except in high-risk groups [10,11]. Althoughntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion have remained unchanged for 20 years [12-14].
Two recent developments are challenging the general
recommendation against use of chemoprophylaxis. First,
postinfectious irritable bowel syndrome (PI-IBS) has been
recognized as an important post-TD sequela, occurring in
approximately 7% of those who experience an enteric infec-
tion, particularly among those with bacterial infection and
a more severe clinical presentation [15,16]. Second, rifaxi-
min, a nonabsorbable antibiotic, has been developed and
may provide a safer alternative for prophylaxis than fluoro-
quinolones, which are known to be quite effective but may
have an unacceptable safety profile. The high volume of
international travel, and, consequently, the high number of
people at risk from acquiring TD, PI-IBS and other postin-
fectious chronic health conditions, create a potentially large
burden of illness that could be prevented with the use of
safe and effective chemoprophylaxis. A number of trad-
itional and systematic qualitative reviews on the use of
chemoprophylaxis, and in particular rifaximin, have been
reported in the past few years and have generally favored
the consideration of rifaximin for prevention of TD among
high-risk groups or the risk-averse traveler [17-21]. How-
ever, those studies rarely assess the quality of the studies
being reviewed and often do not result in a summary effect
estimate of an intervention, which can be of further use for
analytic decision-making and cost-benefit analysis. In
addition, due to the nature of those reviews, they can be
subject to bias and may not adequately consider disparate
findings. Therefore, the objective of this study was to con-
duct a systematic review of the literature on the effective-
ness and safety of rifaximin and fluoroquinolone antibiotics
in the prevention of TD.
Methods
This systematic review and meta-analysis was conducted
according to the guidelines set forth in the Cochrane
Handbook for Systematic Reviews of Interventions [22].
Literature search and study selection
A comprehensive literature search was performed to iden-
tify all randomized, double-blind, placebo-controlled trials
that evaluated effectiveness of rifaximin or a fluoroquino-
lone in preventing TD. Studies that examined other anti-
biotics were excluded because currently the only clinically
relevant antibiotics for preventing TD are rifaximin and
fluoroquinolones. The population of interest comprised
adult civilian or military travelers. Studies were identified
using the electronic databases PubMed (through April
2012) and Embase (through April 2012) and consultation
with experts in the field. The following search strategy was
used on PubMed: “travel* diarrh*” and “travel” (MeSH).
The search was limited to studies on human subjects and
published in English. Citations from retrieved articles wereexamined for primary outcome data completeness, and
studies that reported rates of TD in treatment and control
groups were included in the meta-analysis. In addition,
consultation with experts in the field was used to identify
any missing articles. Eligibility of all articles for systematic
review and meta-analysis was confirmed by two investiga-
tors (SA and MR). The details of the literature search and
study selection are presented in Figure 1.
Data abstraction and risk of bias assessment
Data were collected from each study and recorded on a
data abstraction form, which was designed a priori and
pilot-tested on three studies. Primary data abstraction was
performed by an investigator (SA) and validated independ-
ently by another investigator (JS) before the data were used
for statistical analysis. The primary end point of interest
was the overall risk reduction in incidence of TD in treat-
ment versus control group with the intention-to-treat
(ITT) sample sets of each study. Secondary end points of
interest included per-protocol (PP) risk reduction, efficacy
against moderate to severe TD and safety of prophylactic
antibiotics as measured by rates of drug-attributed adverse
events (AEs) in treatment and control groups and/or other
noted clinically significant AEs. Other information that was
abstracted from each study included first author, publica-
tion name and year published, article title, study design,
country of traveler/travel, year of study, proportion male,
mean/median age, antibiotic dose and frequency, duration
of therapy, travel purpose, and follow-up posttherapy, time
of therapy initiation relative to arrival, list of exclusion cri-
teria, definition of TD used and any other definitions of TD
used (mild, moderate or severe), initial number of subjects
randomized to each study arm, number of subjects that
completed follow-up schedule in each study arm, overall
incidence of TD at week 1 and week 2 after initiating inter-
vention (PP and ITT data), and the incidence of moderate/
severe TD (PP and ITT data).
The risk of bias assessment was performed independently
by two investigators (SA and JS) using guidelines set forth
in the Cochrane Handbook [22]. Seven domains were eval-
uated for bias (random sequence generation, allocation
concealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data, se-
lective reporting and other bias). Criteria for the “other
bias” domain were discussed and specified a priori and
included an assessment of the bias associated with expos-
ure risk (single vs. multiple travel locations, seasonal vari-
ation of travel and the risk level of the participant) and
assessment of adherence to randomized regimen. Each do-
main was assigned one of the following qualitative scores:
“low risk,” “high risk” or “unclear risk.” In general, if there
was evidence of bias, the study was deemed to be “high
risk” for bias for that specific domain. An “other bias” do-
main of risk assessment took into consideration adherence
Figure 1 Flow diagram of literature review, eligibility determination and inclusion in the systematic review and meta-analysis. RCT,
randomized controlled trial.
Alajbegovic et al. Systematic Reviews 2012, 1:39 Page 3 of 10
http://www.systematicreviewsjournal.com/content/1/1/39assessment/reporting and bias associated with exposure
risk. Discordant assessments for each domain of each art-
icle were discussed and adjudicated by reaching consensus
among three investigators (SA, MR and JS).
Data analysis
The proportion of subjects experiencing TD in treatment
and control groups (dichotomous outcome) was used to de-
termine the relative risk of developing TD when a chemo-
prophylactic antibiotic was administered versus placebo.
Relative risks were then pooled independently for fluoroqui-
nolones and rifaximin to determine the overall effect of
chemoprophylactic antibiotic treatment with a 95% confi-
dence interval (CI). Given the heterogeneity of study designs,
population, and dosing regimens, a conservative approach
was employed for all analyses based on a random effects
model of the DerSimonian and Laird (D&L) method to re-
flect both within- and between-study variability. Relative risk
of 1 indicated that chemoprophylaxis did not reduce the in-
cidence of TD any more than placebo. Risk differences were
similarly pooled for purposes of estimating numbers needed
to treat to prevent an episode of TD while traveling.Sensitivity analyses were performed graphically by observa-
tion of differences in pooled relative risks based on within-
drug-class study characteristics and for PP versus ITT data.
Incidence of moderate/severe TD was only pooled for fluoro-
quinolone studies since only one rifaximin study reported
rates of severe TD in treatment and placebo groups. Hetero-
geneity was explored visually and statistically using the het-
erogeneity χ2 and the inconsistency index statistic (I2).
Publication bias was assessed using the method described by
Harbord et al. [23]. All analyses were done using Stata ver-
sion 12.1 software (StataCorp, College Station, TX, USA).
Results
Study selection and study characteristics
Electronic database, manual reference search and consult-
ation with experts in the field yielded 11 studies that were
included in the systematic literature review and 9 that were
included in a meta-analysis [24-34] (Table 1). The study by
Parry et al. was not included in the meta-analysis because
it did not define TD [29], and the study by Taylor et al. was
a human experimental challenge study and thus was not
conducted in a field efficacy setting [32]. Nine studies
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Studies reviewed and included in meta-analysis
Johnson et al. (1986) [24] USA Mexico Language school R, DB, PC Norfloxacin 400 mg daily 115 14 days 88%*
Wistrom et al. (1987) [31] Sweden Africa, Asia, South
America
NS R, DB, PC Norfloxacin 200 mg bid 115 5 to 21 days 84%*
Scott et al. (1990) [34] USA/ Italy Egypt Military R, DB, PC Norfloxacin 400 mg daily 222 7 days 93%*
Rademaker et al. (1989) [30] The
Netherlands
Tunisia Leisure R, DB, PC Ciprofloxacin 500 mg daily 53 8 days 94%*
Heck et al. (1994) [33] USA Central and South
America
Volunteering R, DB, PC Ciprofloxacin 500 mg daily 278 5 to14 days 85%*
DuPont et al. (2005) [26] USA Mexico Language school R, DB, PC Rifaximin 200 mg daily, bid, tid 210 14 days 73%*,a
Armstrong et al. (2010) [25] USA Turkey Military R, DB, PC Rifaximin 1,100 mg daily 95 14 days 67%
Martinez-Sandoval et al.
(2010) [28]
USA Mexico Language school R, DB, PC Rifaximin 600 mg daily 201 14 days 68%*
Flores et al. (2011) [27] USA Mexico Language school R, DB, PC Rifaximin 550 mg daily 98 14 days 28%
Other studies of relevance reviewed but not included in meta-analysis
Parry et al. (1994) [29] UK Nepal Himalayan expedition R, DB, PC Ciprofloxacin 250 mg daily 21 28 days NA
Taylor et al. (2006) [32] NA NA Volunteers R, DB, PC Rifaximin 200 mg tid 25 3 days NA
aRifaximin groups combined. Note: Studies are listed in chronological order by an antibiotic studied. bid = twice daily; tid = three times daily; R, DB, PC = randomized, double-blind, placebo-controlled; NA = not
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with 604 subjects in rifaximin studies and 706 subjects in
fluoroquinolone studies. Four studies examined the effect-
iveness of rifaximin in preventing TD, and one of those
studies (DuPont et al.) had three treatment arms (rifaximin
dosed once, twice or three times daily) and one control
arm (placebo dosed three times daily) [25-28]. The
remaining five studies utilized a fluoroquinolone (three
norfloxacin and two ciprofloxacin) and included single dose
(n = 4) and one twice daily regimen. Overall, among nine
studies, a median attack rate of 34.5% (interquartile range
[IQR] = 20.3% to 53.7%) was found in the placebo groups,
and attack rates were similar between the rifaximin studies
(median 33.1%, IQR = 17.9% to 50.4%) and the fluoro-
quinolone studies (median 34.5%, IQR = 25.6% to 61.0%)
(P = 0.32, Kruskal–Wallis test). There was greater diversity
in traveler populations and geographic destinations for
studies evaluating fluoroquinolone efficacy compared to
those evaluating rifaximin. Duration of intervention was on
average 14 days, and TD definitions were generally similar
across all studies, except one (Heck et al. [33]), where TD
was defined as ≥3 loose stools/8-hour period plus ≥1 asso-
ciated symptom (vs. standard definition of TD, ≥3 loose
stools/24-hour period plus ≥1 associated symptom) which
may have underestimated the incidence of TD in the treat-
ment and placebo groups.
Risk of bias assessment
All studies were deemed to have “low risk” of bias in
domains of allocation concealment, blinding of partici-
pants and personnel, and blinding of outcome assessment
(Figure 2). Although no study specified whether blindingFigure 2 Frequency distribution of assessment of bias scoring amongof outcome assessment took place, investigators deemed
that, owing to the relatively objective nature of the clin-
ical outcome and standard use of definitions, low risk for
bias existed even if the outcome assessment was not
blinded. Four studies did not specify the process of
randomization and were therefore assigned “unclear risk”
for random sequence generation domain. DuPont et al.
[26] had significantly different attrition rates between
treatment and control groups, and Heck et al. [33]
reported a relatively high attrition rate that was not ad-
equately handled/reported; therefore, both studies were
assigned “high risk” for the incomplete outcome data do-
main. Unclear risk in incomplete outcome data domain
was assigned to the study by Armstrong et al. because of
the low number of stool specimens collected, an end
point that was prespecified in the Methods section of the
study [25]. A single study had high risk for bias in select-
ive data reporting domain due to the fact that an ITT
outcome for the primary end point was not available [33].
Primary outcome: prevention of TD in ITT analyses
ITT data from studies examining fluoroquinolones and
rifaximin were pooled by drug class to determine
whether antibiotic chemoprophylaxis was effective in
preventing TD (Figure 3). Among the rifaximin studies,
two of the four studies showed a statistically significant treat-
ment effect and one demonstrated marginal statistical sig-
nificance. There was no observed significant difference of
risk reduction among dosing regimens in the DuPont et al.
study, and the overall pooled D&L effect (relative risk [RR])
estimate for all studies combined was 0.33 (95% CI = 0.24 to
0.45), equating to a protective efficacy of 67% (95% CI = 55%included studies in meta-analysis (n = 9).
Figure 3 Pooling of studies by drug class for intention to treat analysis. RR = relative risk; PE = protective efficacy; CI = confidence interval.
1. Regimen using ciprofloxacin. 2. Regimen using norfloxacin.
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P = 0.377; I2 =3.1%). In terms of absolute risk reduction,
pooled D&L summary estimates found that rifaximin
chemoprophylaxis decreased TD attack rates by a mean of
22.1% (95% CI = 6.3% to 37.9%) equating to a number
needed to treat (NNT) of 4.5 people (95% CI = 2.6 to 15.9)
who needed chemoprophylaxis to prevent one episode of
TD. All five of the studies evaluating fluoroquinolone-based
regimens showed a statistically significant effect with a
pooled D&L effect RR estimate of 0.12 (95% CI = 0.07 to
0.20), equating to a protective efficacy of 88% (95% CI = 80%
to 93%) favoring chemoprophylaxis (heterogeneity χ2 = 1.25,
P = 0.87; I2 =0.0%). Risk reduction for fluoroquinolone-class
antibiotics was estimated with a D&L pooled mean of 35.5%
(95% CI = 21.2% to 49.8%), equating to a NNT of 2.8 (95%
CI = 2.0 to 4.7). For both drug classes, there was no indica-
tion of publication bias (rifaximin, P = 0.63; fluoroquino-
lones, P = 0.56).
Further exploration of the studies by drug class was con-
ducted and based on a subanalysis of the effect of pooling
data from stratification of the Dupont et al. study including
once-daily treatment arm, treating three different treatment
arms as if they were independent studies, and combining
results from three different treatment arms [26]. When
slightly different pooled relative risks were examined, all
analytical strategies still favored chemoprophylaxis with
rifaximin over placebo (daily: RR = 0.34, 95% CI = 0.22 to
0.51; independent: RR = 0.32; 95% CI = 0.24 to 0.43; com-
bined: RR = 0.33; 95% CI = 0.24 to 0.45). On the basis ofthe similarity of these effect estimates, a decision was made
to use a combined estimate from all three dosing regimens
for purposes of further analysis. Further exploration of het-
erogeneity within each drug class was challenging, given
the small number of studies. The study by Flores et al.
stands out compared to the other studies included in this
systematic review and differed only in nonsummer enroll-
ment period compared to the other studies conducted in
similar populations in Mexico [27].
Secondary outcomes: prevention of TD in PP analyses and
moderate to severe disease
Analysis of efficacy in the PP sample set was available for all
four studies in the rifaximin drug class. (Note: PP data were
provided by one of the coauthors, MR, for the Armstrong
et al. study [25].) The D&L summary pooled RR effect esti-
mate was 0.27 (95% CI = 0.17 to 0.43) and tended toward
moderate heterogeneity (heterogeneity χ2 = 5.43, p = 0.14;
I2 = 44.7%). Only three studies within the fluoroquinolone
drug class included outcome data from subanalysis of mod-
erate to severe TD and compared to placebo, though defini-
tions varied across these studies. Rademaker et al. defined
severe diarrheal illness as “symptoms of vomiting and/or
fever >38°C,” whereas Heck et al. and Johnson et al.
defined confirmation of moderate to severe TD by the pres-
ence of Shigella spp. [24,30,33] and outcome events of
moderate to severe TD was low (five, two and three cases,
respectively, for both treatment and placebo groups com-
bined). Considering these limitations, however, a pooled
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(95% CI = 0.095 to 2.71) with low heterogeneity (hetero-
geneity χ2 = 2.08, P = 0.354, I2 = 3.8%) was found and
represented poorer efficacy compared to prevention against
all levels of TD severity.
Secondary outcome: safety and adverse events
The incidence of treatment emergent AEs was not reported
consistently across studies. AEs of note occurred in subjects
taking fluoroquinolones. Treatment emergent AEs reported
in studies examining fluoroquinolones included a rash that
resolved after norfloxacin was discontinued [24], enlarge-
ment of parotid glands [31], and sunburn in a subject tak-
ing ciprofloxacin [30]. Otherwise, all reported rates of AEs
were similar between treatment and control groups, and no
clinically significant events developed during chemoprophy-
laxis with rifaximin or a fluoroquinolone.
Review of studies not included in meta-analysis
Two clinical trials not included in the meta-analysis should
be considered in review of the potential effectiveness of anti-
biotic chemoprophylaxis for the complementary evidence
they may bring forth. In a letter to the editor, Parry et al.
described a small, double-blind, randomized, placebo-
controlled trial of 250 mg of ciprofloxacin compared to pla-
cebo in a group of British mountaineers trekking in the
Himalayas [29]. The primary end point was not a case defin-
ition of TD, but rather a decision by the expedition medical
officer to break the code and to stop the trial medication.
Among 21 participants (10 ciprofloxacin and 11 placebo)
who completed the study, 6 of 11 placebo recipients met the
end point criteria, whereas none of the 10 taking ciprofloxa-
cin met the end point (P < 0.05). It was also noted that
gastrointestinal complaints such as loose stools, cramping
and nausea were decreased among those taking ciprofloxacin
compared to placebo.
Taylor et al. reported the efficacy in a human experimen-
tal challenge study in which 15 volunteers were treated
with 200 mg tid rifaximin and 10 were randomized to pla-
cebo in a Shigella flexneri 2a (2457 T) challenge at 1,500
colony-forming units. In this study, there were no cases of
shigellosis in the rifaximin group, compared with 6 of 10 in
the placebo group becoming ill (P = 0.001) [32].
Discussion
This systematic review summarizes the findings of several
studies showing a comparative advantage of antibiotic
chemoprophylaxis for the prevention of TD. With respect
to rifaximin chemoprophylaxis, two studies (Flores et al.
and Armstrong et al.) did not show that chemoprophylaxis
with rifaximin reached a statistically significant difference in
preventing TD compared to placebo [25,27]. In both stud-
ies, the incidence of TD in the control group was relatively
low (8 of 48 (17%) and 9 of 47 (19%), respectively), whichcould have explained the findings given that the sample size
calculations were based on the expected incidence of TD of
40% and thus may have been too small to detect the true ef-
fect of rifaximin in preventing TD. Furthermore, though
studies utilizing rifaximin were limited to only two regions,
there appeared to be a consistent effect of protection at 67%
(D&L 95% CI = 55% to 76%) with little heterogeneity (het-
erogeneity χ2 = 3.09, P = 0.377; I2 =3.1%), and the study by
Taylor et al. suggests that rifaximin may be effective against
more invasive pathogens occurring in other common travel
destinations [32]. However, until such studies are done in
field settings (and against a broader range of invasive patho-
gens to include nontyphoid Salmonella and Campylobacter),
routine chemoprophylaxis against TD with rifaximin may
not be appropriate if a traveler is going to destinations where
diarrheagenic Escherichia coli are less common.
The effectiveness of fluoroquinolone antibiotics would ap-
pear to be greater than rifaximin, which is not surprising,
given the broader spectrum of coverage and systemic distri-
bution of this drug class. Pooled estimates of fluoroquino-
lone efficacy were 88% (95% CI 80% to 93%) with little
evidence of heterogeneity (heterogeneity χ2 = 1.25, P = 0.87;
I2 = 0.0%), though less effective when moderate to severe
TD as an outcome is considered (summary D&L efficacy of
49%). It is important to note that studies examining fluoro-
quinolones were not as current as the studies that examined
rifaximin (publication 1986 to 1994 vs. 2005 to 2011). As
sanitation and hygiene conditions improve, resistance to
fluoroquinolones emerges, and geographical patterns of re-
sistance change (and keep evolving), older data citing fluoro-
quinolone use for chemoprophylaxis may become obsolete.
The data from older studies of the use of fluoroquinolones
may be less contemporaneous, but it is still valuable as it
adds perspective and places newer data from rifaximin stud-
ies into context.
Although such a meta-analysis of the efficacy of antibiotics
for TD prevention is interesting, the results do not necessar-
ily compel one to embrace chemoprophylaxis as a potential
solution. Even in the face of efficacy data for safer antibiotics
such as rifaximin, the prevailing consensus is against wide-
spread use exemplified by Dr. Gorbach, Chairman of the
1985 NIH Consensus Development Panel, who wrote an ac-
companying editorial to the first report of rifaximin diar-
rhea prophylactic efficacy in 2005 [13]. Gorbach’s concerns
included potential unintended adverse consequences, such
as safety issues, uncertain protection against invasive patho-
gens, and microbiologic adverse effects, that may not yet be
apparent in the small number of studied individuals. Dr.
Gorbach concluded with the statement, “Rapid and judicious
treatment of diarrhea, not antibiotic prophylaxis, is the best
recommendation for most travelers.”
Although these concerns still prevail today, a new consid-
eration regarding the potential risk of postinfectious chronic
health consequences of TD has arisen. Serious sequelae
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[36] have long been known to be associated with infections
causing TD, but they are relatively infrequent. Most notable
has been the accumulating evidence associating TD with
postinfectious irritable bowel syndrome. Two separate sys-
tematic reviews have now been published which conclude
that roughly 1 of 11 people who develop acute diarrheal in-
fection may go on to develop PI-IBS [15,16]. Other studies
are also reporting TD risk with other common postinfec-
tious functional gastrointestinal disorders [37-40]. With TD
specifically, there have been six studies among traveler
populations, all of which have shown an increased risk of
PI-IBS among travelers who develop TD compared to those
who do not develop TD [39-44]. Factors which appear to be
associated with increased risk of PI-IBS include fever, illness
severity, duration, infection with an invasive pathogen, and
concomitant acute stress. Furthermore, this risk remains
elevated for at least 3 years after the infection [16] and has
been described to persist in 57% after 6 years in one study
and 76% after 5 years in another [45,46].
Thus, the recognition of both the acute and chronic con-
sequences associated with TD diarrhea may change the risk-
balance and value equation for antibiotic chemoprophylaxis.
A recent economic analysis by Lundkvist et al., who evalu-
ated the potential cost-effectiveness of a vaccine against en-
terotoxigenic E. coli, described the cost of a TD event of
$1,460 or $1,996 for a leisure or business traveler, respect-
ively (including value of travel, value of time, and medical
costs) [47]. With regard to IBS, in a review of 18 economic
studies conducted in the United States and United Kingdom,
direct and indirect cost per patient-year were estimated be-
tween $700 and $12,000 (2002) [48]. In this systematic re-
view, we found a NNT with chemoprophylaxis to prevent
TD during travel of 2.8 (95% CI = 2.0 to 4.7) for fluoroqui-
nolones and 4.5 (95% CI = 2.6 to 15.9) for rifaximin. A back-
of-the-envelope calculation would suggest that to prevent
the cost of acute disease, a single-dose, 14-day regimen of
rifaximin 550 mg (at $22.61 per dose, $316.58 regimen)
would provide a net benefit of $35 for a leisure traveler
($1,460 – (4.5×$316.58)) and a $571 net benefit for the
average business traveler to an average-risk region. Fluoro-
quinolones at less than $1.00 per dose (ciprofloxacin) would
appear to be even more cost-effective using a simplistic cal-
culation. However, such cost savings need to be balanced by
the cost of potential AEs associated with antibiotics. Interest-
ingly, in this systematic review, there were no treatment
emergent-related AEs reported for any of the studies, though
the inclusion of risk of Clostridium difficile infection and
fluoroquinolone-related tendonopathies ought to be consid-
ered more formally in an economic analysis. If one were to
more comprehensively consider the value added in prevent-
ing PI-IBS and other chronic health consequences, the bene-
fits of chemoprophylaxis in acute and chronic disease
prevention may appear to outweigh the risks associated withchemoprophylaxis. Clearly, future studies are needed to bet-
ter define the economic cost associated with PI-IBS and
whether chemoprophylaxis with rifaximin or fluoroquino-
lones can be used safely to prevent such sequelae.
The present review includes a comprehensive literature
search, a priori inclusion and exclusion criteria, standardized
data abstraction, risk of bias scoring, and current analytic
methods, all of which reduce the potential bias in the result-
ant population of studies used for analysis. However, the small
number of studies and the lack of studies conducted among a
variety of study population types and geographic regions limit
the broad application of these results beyond young healthy
travelers and, for rifaximin, to regions outside Central Amer-
ica, where diarrheagenic E. coli may not predominate.
Though comprehensive, our search strategy might not have
identified all eligible studies. We did not find heterogeneity in
study effect estimates, but the studies evaluating fluoroquino-
lones were not current and thus may have been subject to
changes in traveler population demographics and secular
trends of antimicrobial resistance. Therefore, translation of
results from this type of controlled setting to other popula-
tions who may be less healthy or subject to different travel or
treatment environments need to be validated by additional
studies. This systematic review afforded an objective assess-
ment of study design and risk of bias for the population of
chemoprophylaxis trials included. Although the risk of bias
for most domains was considered low, the authors felt that
there was incomplete data reporting for some studies, which
could have included important secondary outcomes related
to per-protocol or efficacy evaluable analyses and efficacy
against moderate to severe disease. In addition, it was noted
that not all studies included information on how they ensured
or measured treatment adherence and what potential effect
such nonadherence may have had on study results. Given the
known problem of medication adherence with malaria
chemoprophylaxis, such an assessment for TD adherence
within these trial settings would be informative [49,50]. Last,
some studies had significant lost to follow-up rates, which,
though generally balanced across treatment arms, raises fur-
ther concern about self-selection bias and the generalizability
of these results. Future studies ought to consider better meth-
ods to ensure avoidance of dropouts and losses to follow-up,
which can be a challenge in a travel setting.
Conclusions
It is crucial that clinicians, including pharmacists who practice
in a travel clinic setting, stay well-informed on geographical
patterns, itineraries, traveler behaviors and areas where the
risk of developing TD is high (high-risk areas). If a traveler
is planning on taking a short-term trip (≤14 days in dur-
ation) to an area where the risk for developing TD is high
and diarrheagenic E. coli pathogens predominate, the data
reviewed in this study support the authors’ opinion that
routine chemoprophylaxis with rifaximin may be a
Alajbegovic et al. Systematic Reviews 2012, 1:39 Page 9 of 10
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